-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

Benzinga·11/05/2026 20:10:28
Listen to the news
Leerink Partners analyst Thomas Smith maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $50 to $54.